The branch aims to support growing business activities in China.
Lipid ingredients specialist Enzymotec (Migdal HaEmeq, Israel) has opened an office in Shanghai-a branch the company says aims to support growing business activities in China. The company has a presence in more than 40 countries.
“Southeast Asia in general, and China in particular, have become key markets for us due to the economic developments in the region,” said Enzymotec CEO Ariel Katz, PhD, in a press statement.
Enzymotec develops and manufactures lipid-based nutraceutical ingredients. Its business is divided in three segments: infant nutrition (with InFat, a clinically proven ingredient that mimics the fat of human milk and is marketed through Advanced Lipids AB, a joint venture of AAK and Enzymotec); bioactives; and pharmaceutical.